Cachexia News and Research

RSS
Cachexia is a condition which denotes the excessive loss of weight. It occurs because of the depletion of adipose tissue and muscle mass in people who are not trying to lose weight.
Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Scientists discover sign of early development of pancreatic cancer

Scientists discover sign of early development of pancreatic cancer

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

Study pinpoints molecular cause of cachexia, hints at a potential treatment

Study pinpoints molecular cause of cachexia, hints at a potential treatment

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Study highlights impact of diet, exercise on prevention, treatment and survivorship of cancer

Study highlights impact of diet, exercise on prevention, treatment and survivorship of cancer

IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

IRB Barcelona scientists develop new drug target to prevent muscle deterioration in certain diseases

New antibody could boost strength, muscle mass in patients with cancer and other diseases

New antibody could boost strength, muscle mass in patients with cancer and other diseases

Chronic bronchitis could indicate COPD subtype

Chronic bronchitis could indicate COPD subtype

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting

Study reveals that tumors factors inhibit repair of damaged muscle fibers during cancer wasting

Study on the development of internet-based physical activity intervention presented at EULAR 2013

Study on the development of internet-based physical activity intervention presented at EULAR 2013

Doctors should conduct frail screening to prevent bad outcomes

Doctors should conduct frail screening to prevent bad outcomes

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

XBiotech announces enrollment of first patient in Xilonix Phase III trial for treatment of cachexia

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

Inflammation could hinder energy intake in advanced cancer

Inflammation could hinder energy intake in advanced cancer

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows